Selected article for: "allergen challenge and current study"
Author: Leaker, Brian R.; Singh, Dave; Lindgren, Sam; Almqvist, Gun; Eriksson, Leif; Young, Barbara; O’Connor, Brian
Title: Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study
  • Document date: 2019_12_19
    • ID: 15e043uf_50
    Snippet: Administration of AZD8848 directly to the lung has previously been shown to inhibit eosinophilia and IL-13 levels for up to 4 weeks post-treatment following ovalbumin challenge in the Brown Norway rat [35] . In the current study there were no significant changes observed in sputum cytokine or eosinophil counts with intranasal AZD8848 treatment 1 week post-dosing, either before or after allergen challenge. Although there was a trend towards a redu.....
    Document: Administration of AZD8848 directly to the lung has previously been shown to inhibit eosinophilia and IL-13 levels for up to 4 weeks post-treatment following ovalbumin challenge in the Brown Norway rat [35] . In the current study there were no significant changes observed in sputum cytokine or eosinophil counts with intranasal AZD8848 treatment 1 week post-dosing, either before or after allergen challenge. Although there was a trend towards a reduction in Th2 cytokines and sputum eosinophils prior to allergen challenge 1 week after the last dose, this did not reach statistical significance. However, the range of all sputum cell data was n = 12 to 19 per group from a total number of subjects of n = 25 (placebo) or n = 26 (AZD8848). In our opinion, this reduced number of sputum samples in each respective treatment group was too low to demonstrate statistical difference between the groups.

    Search related documents:
    Co phrase search for related documents
    • allergen challenge and eosinophil count: 1
    • allergen challenge and post dose: 1
    • allergen challenge and significant change: 1
    • allergen challenge and sputum cytokine: 1, 2
    • allergen challenge and sputum eosinophil: 1, 2
    • allergen challenge post dose and post dose: 1
    • current study and eosinophil count: 1, 2, 3, 4
    • current study and post dose: 1, 2
    • current study and reduce number: 1, 2, 3
    • current study and significant change: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • eosinophil count and level eosinophilia: 1, 2
    • eosinophil count and significant change: 1, 2
    • eosinophil count and sputum cytokine: 1
    • eosinophil count and sputum eosinophil: 1, 2, 3, 4
    • group statistical difference and significant change: 1, 2
    • level eosinophilia and sputum eosinophil: 1
    • post dose and significant change: 1, 2, 3, 4
    • reduce number and significant change: 1, 2
    • significant change and sputum cytokine: 1